Dealflow | March 28, 2017

Women-led Pivotal bioVenture closes $300 million fund for early-stage drugs

The team at


Women Rising

Tracy Saxton, who was the investment director for the Roche Venture Fund and for SV Life Sciences Advisers, has closed the first fund for her new firm, Pivotal bioVenture Partners.

Pivotal is seeking to fill a capital gap in early-stage treatments between drug discovery and early clinical development.

Saxton was backed by the Nan Fung Group in Hong Kong. Healthcare, like finance and tech, is notoriously light on women leaders.

Increasingly, women are starting their own healthcare investment funds rather than trying to climb the ranks of established firms, says GE Ventures’ Lisa Suennen.

Biomatics Capital, co-led by Julie Sunderland, formerly with the Bill & Melinda Gates Foundation, recently announced it had raised $200 million for its first fund.

This post originally appeared in ImpactAlpha’s daily newsletter. Get The Brief.

Photo credit: Endpoints News